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Abstract Both estrogen (E) and progesterone (P) are
implicated in the etiology of human breast cancer. Defining
their mechanisms of action, particularly in vivo, is relevant
to the prevention and therapy of breast cancer. We
investigated the molecular and cellular mechanisms of E
and/or P-induced in vivo proliferation, in the normal rat
mammary gland and in hormone-dependent rat mammary
cancers which share many characteristics with the normal
human breast and hormone-dependent breast cancers. We
show that E+P treatment induced significantly greater
proliferation in both the normal gland and mammary
cancers compared to E alone. In both the normal gland
and tumors, E+P-induced proliferation was mediated
through the increased production of amphiregulin (Areg),
an epidermal growth factor receptor (EGFR) ligand, and the
activation of intracellular signaling pathways (Erk, Akt,
JNK) downstream of EGFR that regulate proliferation. In
vitro experiments using rat primary mammary organoids or
T47D breast cancer cells confirmed that Areg and the
synthetic progestin, R5020, synergize to promote cell
proliferation through EGFR signaling. Iressa, an EGFR
inhibitor, effectively blocked this proliferation. These
results indicate that mediators of cross talk between E, P,
and EGFR pathways may be considered as relevant
molecular targets for the therapy of hormone-dependent
breast cancers, especially in premenopausal women.
Keywords Progesterone . Estradiol . Progesterone
receptor . Amphiregulin . EGFR .Mammary gland .
Proliferation .Mammary cancer
Introduction
Estrogen (E) and progesterone (P) are implicated in the
etiology of breast cancer [1, 2]. However, their precise
cellular and molecular mechanisms of action in the breast,
particularly in vivo, are not well understood. Determining
how E and/or P contribute to proliferation is important for
understanding their roles in the normal breast and in the
etiology of breast cancer. While the role of E in breast
cancer has been widely studied, less is known about the
role of P. This is particularly relevant because, in
postmenopausal women, hormonal therapy with estrogen
plus progestin (compared to estrogen alone) significantly
increases breast cancer risk [2].
P imparts its biological action via two major progesterone
receptor (PR) isoforms, PRA and PRB. Numerous lines of
evidence suggest that PRA and PRB have distinct physio-
logical functions in vitro and in vivo. Experiments using
stable monoclonal cell lines of T47D human breast cancer
cells that are PR negative, express only PRA, or express only
PRB, have shown that PR isoforms differ in their ability to
activate gene transcription, to interact with cytoplasmic
signaling cascades, and in their requirements for activation
by ligand [3–5]. Studies in mice lacking or overexpressing
PR isoforms in the mammary gland indicate that PRA may
be involved in sidebranching, while PRB is critical for
lobuloalveolar formation during pregnancy [6–8].
Studies in the T47D breast cancer cell line have
demonstrated that P action is closely interconnected with
epidermal growth factor receptor (EGFR) signaling [9–11].
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PRB seems to be a critical mediator of the cross talk
between P and EGFR pathways. P action via PRB but not
PRA leads to an autocrine activation of EGFR that results
in sustained phosphorylation of Erk [11]. In turn, epidermal
growth factor (EGF) treatment activates several intracellular
signaling pathways downstream of EGFR that dramatically
increase transcriptional activity of PRB both in the presence
and absence of ligand [12, 13]. It is currently not known
whether the cross talk between P and EGFR signaling takes
place in the normal breast and primary mammary cancers in
vivo.
Recent studies of PR isoform expression in the normal
human breast have shown that the developmental pattern of
PR isoform expression, PR isoform colocalization, and cell-
type specific expression of PR isoforms are similar to those
observed in the rat mammary gland [14]. Both the human
breast and rat mammary gland have a similar ductal-lobular
organization [15, 16], and mammary cancers induced in
the rat are predominantly hormone-dependent similar to the
majority of human breast cancers. Therefore, studies on the
mechanisms of P action in the normal rat mammary gland
and hormone-dependent rat mammary cancers may provide
insights into P action that are relevant to the human breast
and breast cancer.
We report that E and P work together in vivo in cells co-
expressing estrogen receptor α (ERα), PRA, and PRB to
induce robust proliferation in both the normal mammary
gland and hormone-dependent mammary cancers through
the induction of amphiregulin (Areg). We propose that Areg
acts as an autocrine/paracrine EGFR ligand to activate
EGFR downstream signaling that, in concert with P acting
through PRB, promotes proliferation in ERα+PRA+PRB+
and ERα−PRA−PRB+ cells. Furthermore, in vitro experi-
ments showed that Iressa, an EGFR inhibitor, can effec-
tively block this pathway and proliferation. The conserved
cross talk between E, P, and EGFR signaling in mammary
tumors suggests that combining EGFR inhibitors with
antiestrogen therapy may prove beneficial in the treatment




Normal Mammary Gland Adult 18-week-old Sprague–
Dawley rats (Charles-River Laboratory, Raleigh, NC,
USA) were ovariectomized (OVX), and 2 weeks later, the
animals were injected subcutaneously with vehicle control,
E (17 μg/kg), P (15 mg/kg), or a combination of E+P
(17 μg/kg+15 mg/kg) daily for 3 days. Sham-operated,
vehicle-treated rats served as ovary-intact control (OI). For
Elvax pellet implant experiments, ovariectomized animals
were implanted in the right inguinal mammary gland with
an Elvax 40P (DuPont Inc.) pellet containing human
recombinant Areg (Sigma, St. Louis, MO, USA) (10 μg
Areg+0.2 mg bovine serum albumin (BSA)/pellet); the
contralateral inguinal gland was implanted with a control
pellet containing only BSA (0.2 mg) as previously
described [17]. Control, E, or P injections daily for 3 days
were initiated immediately after pellet implantation.
Mammary Cancer For mammary cancer development,
ovariectomized 50-day-old rats were implanted with
silastic pellets containing E (2.5 mg/1 cm) with or without
four pellets releasing P (50 mg/4 cm) and treated with a
single intragastric dose (50 mg/kg) of 7,12-dimethylbenz
[α]anthracene. Normal mammary tissues and tumors were
fixed in 10% buffered formalin and paraffin-embedded for
immunohistochemical analysis or flash-frozen in liquid
nitrogen and stored at −80°C for messenger RNA
(mRNA) or protein analysis. For all experiments, animals
were euthanized 2 h after i.p. injection with 5-bromo-2-
deoxyuridine (BrdU) (Sigma) (70 mg/kg). All animal
handling procedures were approved by the Michigan State
University Committee on Animal Use and Care.
Cell Lines T47D cell lines, T47D-Y (lacking PR), T47D-
YA (expressing only PRA), and T47D-YB (expressing only
PRB) [18], were generously provided by Dr. KB Horwitz
(University of Colorado). Cells were grown in minimal
essential media and 5% fetal bovine serum as described
[11]. For experiments, cells were cultured in phenol red-
and serum-free media for 24 h, treated with synthetic
progestin R5020 (20 nM) with or without Iressa (gefitinib,
ChemieTek, Indianapolis, IN, USA; 500 nM) or RU486
(mifepristone, Calbiochem, La Jolla, CA, USA; 100 nM)
for 24 h, and then treated with 25 nM Areg for 30 min
according to the published protocol for these cell lines [9].
Analysis of the Cell Cycle in T47D Cells Cells were plated
at density 6×105 cells/well in six-well plates in the
presence of serum. Cells were cultured for 48 h in serum-
free conditions, treated for 24 h, trypsinized, and fixed with
80% methanol. Cells were stained with 4′,6-diamidino-2-
phenylindole (DAPI) (1 μg/ml) and analyzed with the BD
Vantage Turbo SE flow cytometer and ModFit3.2 software.
Primary Culture of the Rat Mammary Organoids in
Collagen Gel Primary culture of mammary organoids in
collagen gels was performed as described [19]. Organoids
were cultured in serum-free media containing 0.1% BSA
and supplemented with 1× essential amino acids, 0.5× non-
essential amino acids, 0.5× vitamins (Invitrogen, Carlsbad,
CA, USA), 1× serum replacement 1 reagent, and 0.2× ITS
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(insulin-transferrin-sodium selenite) media from Sigma for
5 days. Organoids were treated with P (20nM), Areg
(25 nM), or Areg+P. Proliferation was assessed by BrdU
incorporation for the last 24 h of culture [19]. Collagen gels
were fixed in 10% buffered formalin, paraffin-embedded,
and sectioned for immunohistochemical analysis.
Antibodies The antibodies used in the study were mouse
monoclonal anti-human PR antibody (hPRa7), PRA-
specific in immunohistochemistry [20], and anti-human
PRB (hPRa6), PRB-specific in immunoblot and immuno-
histochemistry (Neomarkers, CA, USA; dilution 1:100
and1:25, respectively) [20]. Rabbit polyclonal anti-mouse
PRB antibody (B15, custom-made by Affinity Bioreagents,
Golden, CO, USA; 1:800) was used for immunohistochem-
istry. The B15 rabbit antibody was developed to specifi-
cally detect PRB in the mouse and rat that differs
significantly from the human PRB in the B-specific N-
terminal region and to reduce the issue of potential for
cross-reactivity between two mouse monoclonal antibodies
(hPRA6 and hPRA7) that detect human PRA and PRB. The
B15 antibody has been shown previously to be specific for
the detection of only PRB by immunohistochemistry and
immunoblot in rat mammary tissue [21]. Rabbit polyclonal
anti-PR antibody (DAKO A0098, Carpinteria, CA, USA)
detects both PRA and PRB by immunoblot. Rabbit
polyclonal anti-α-smooth muscle actin (SMA) (1:200),
mouse monoclonal anti-α-tubulin (1:400), anti-cytokeratin
18 (1:100) antibody (Abcam, Cambridge, MA, USA),
rabbit polyclonal anti-phospho-Akt1/2/3 (Ser473) (1:75),
anti-total Erk (1:200), goat polyclonal anti-β-actin
(1:1,000) and anti-phospho-c-Jun (Ser73) (1:25), mouse
monoclonal anti-c-Fos (1:50), anti-Areg (1:100), anti-
phospho-Erk (Tyr204) (1:100), rabbit polyclonal anti-
nuclear factor kappa B (NFκB) (p65) (1:50), antibody
specific to phospho-serine (1:100) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), rabbit polyclonal anti-cyclin
D1 (Biosource, Camarillo, CA, USA; 1:100), rabbit
polyclonal anti-EGFR (1:100), mouse monoclonal anti-
phospho-EGFR (Tyr1068) (1:100) (both from Cell Signal-
ing, Beverly, MA, USA), goat polyclonal anti-Areg (R&D
Systems, Minneapolis, MN, USA; 1:40), rabbit polyclonal
anti-β-catenin, anti-keratin 18 (both from Sigma, St. Louis,
MO, USA; 1:200), mouse monoclonal anti-proliferating
cell nuclear antigen (PCNA) (Calbiochem, San Diego, CA,
USA; 1:100), mouse monoclonal anti-ERα (6F11, Novo-
castra, UK; 1:10), and sheep polyclonal anti-BrdU antibody
(Biodesign International, Saco, ME, USA; 1:25) were used
in the experiments. AlexaFluor488, AlexaFluor546, or
AlexaFluor633-labeled secondary antibodies against
mouse, rabbit, sheep, or goat were purchased from
Invitrogen, Eugene, OR, USA. Nuclei were counterstained
with DAPI.
Immunohistochemistry Immunoperoxidase staining, single,
double, or triple immunofluorescent labeling were per-
formed as described [21] with modification for the triple
labeling where the combination of the mouse, rabbit, and
goat or mouse, rabbit, and sheep primary antibodies were
used. Images were captured with a Nikon inverted epi-
fluorescence microscope or an Olympus Fluoview laser
scanning confocal microscope (Mager Scientific, Dexter,
MI, USA) and analyzed with MetaMorph software
(Molecular Devices Corp., Downington, PA, USA).
Immunoblot and In-cell Western Analysis For immunoblot
analysis, samples were homogenized in radioimmunopreci-
pitation buffer (Santa Cruz Biotechnology) according to the
manufacturer’s instructions and resolved on 4–20%
NuPAGE gels (Invitrogen). To detect phospho-PRB,
600 μg of total protein was immunoprecipitated with a
mixture of anti-PR antibodies (DAKO and hPRa7) and
blotted onto nitrocellulose membrane. The membrane was
incubated with phospho-serine specific antibody (primary
mouse mAb and IRDye™800-labeled secondary antibody).
This was followed by incubation with PRB-specific
antibody (primary rabbit polyclonal B15, 1:500;
IRDye™680-labeled secondary antibody). Using the Li-
Cor Odyssey detection system allowed simultaneous
detection of both antibodies. Colocalization of the two
antibodies (anti-phospho-serine and anti-PRB) was used to
measure the level of phospho-PRB. Fold change data were
obtained by normalization of the band density to the density
of α-tubulin, β-actin, keratin 18, or IgG band (in
immunoprecipitation experiments), followed by normaliza-
tion of obtained values to the value in the control group.
For in-cell Western analysis, cells were gown in 96-well
plates in triplicates, treated with Areg, R5020 with or
without inhibitors as described above, fixed in 10%
buffered formalin, and incubated with primary antibodies
for phospho-Akt/tubulin or phospho-Erk/total Erk as
described [22]. Anti-mouse or anti-rabbit IRDye™680 or
IRDye™800-labeled secondary antibody was purchased
from Li-Cor Biosciences, Lincoln, NE, USA (dilution
1:4,000 for immunoblot; 1:500 for in-cell Western).
Membranes and 96-well plates were scanned and analyzed
with a Li-Cor Odyssey infrared scanner.
Real-Time RT-PCR Total RNA was isolated using Trizol
reagent (Invitrogen) according to the manufacturer’s
instructions. Preparation of cDNA and real-time PCR
analysis were performed as previously described [23].
Expression levels of genes of interest were normalized to
18S expression [24]. Primers specific for the rat EGF,
epiregulin (Ereg), Epigen, Areg, betacellulin (Btc), TGFα,
heparin-binding EGF-like growth factor, EGFR, receptor
activator of nuclear factor kappa B ligand (RANKL), and
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Wnt4 were purchased from SA Biosciences, Frederick,
MD, USA. Delta-Delta CT method was used to calculate
changes in gene expression. Tests were performed on RNA
isolated from a minimum of three animals or four tumors
per experimental group with three technical replicates for
each sample. For EGFR ligands, fold change was calculated
compared to EGF expression level because it was the
lowest expressed EGFR ligand in OVX control (threshold
cycle ∼29).
Quantitation and Statistical Analysis The number of BrdU+
cells detected by immunoperoxidase staining and the number
of PRA, PRB, BrdU, or SMA+ cells, and colocalization of
these markers detected by immunofluorescent labeling were
quantitated as previously described [21]. In mammary tissue
sections, the percent of positive cells was determined for
ducts and lobules. The number of positive cells was
expressed as the percent of total epithelial cells counted.
Results were presented as mean ± SEM and differences were
considered significant at P<0.05 by ANOVA/MANOVA
with Duncan’s post hoc test where appropriate.
Results
E and P Synergistically Induce Proliferation in Cells
That Express PRB in the Normal Mammary Gland
Cell-type-specific proliferation in normal mammary gland
was analyzed by immunohistochemical detection of BrdU
incorporation and α-SMA, a specific marker of myoepi-
thelial cells (Fig. 1a). Combined 17-β-estradiol plus
progesterone (E+P) treatment of adult OVX rats produced
a robust synergistic increase in the proliferation of epithelial
cells (both luminal and myoepithelial cells) in ducts (∼24%)
and lobules (∼39%). E alone induced significantly less
proliferation in ducts (∼4%) and in lobules (∼3%), while P
alone did not increase proliferation. The relative effects of
E vs. E+P on proliferation were supported by immunoblot
detection of a higher level of PCNA protein in E+P-treated
glands (Fig. 1b).
Since we observed that both E and P were required for
robust proliferation, we analyzed the hormonal regulation
of PR isoforms and their colocalization with ERα (Fig. 2).
PRA expression was E-dependent (Fig. 2a–c); PRA-
positive cells were virtually undetectable in OVX control
(C) or P-treated glands. Treatment with E or E+P restored
PRA expression to the level observed in ovary-intact
animals. In contrast to PRA, PRB expression was E and P
independent (Fig. 2a–d).
Virtually all luminal cells expressing PRA also co-
expressed ERα (Fig. 2e) and PRB (Fig. 2a–c). Thus, in OI
glands, 98.0±0.9% of ERα-positive (ERα+) cells co-
expressed PRA and 93.9±1.2% of PRA+ cells co-
expressed ERα. In contrast, a significant population of
PRB+ cells did not co-express PRA (Fig. 2a–c) or ERα
(Fig. 2f). Based on these results, we conclude that there are
two major populations of steroid receptor-positive luminal
cells: cells that co-express ERα, PRA, and PRB and cells
that express only PRB. As previously reported, myoepithe-
lial cells that expressed only PRB were also detected (data
not shown) [21]. However, since ERα, PRA, and PRB were
colocalized exclusively in luminal cells and luminal cells
compose the bulk of hormone-dependent breast cancers, the
following experiments have focused on P effects in the
luminal cell compartment.
The majority of proliferating BrdU+ cells expressed only
PRB (Fig. 2g). This was especially true for ducts in E-
treated glands and for both ducts and lobules in E+P-treated
glands. Only a smaller fraction of the proliferating cells co-
expressed PRB, PRA, and ERα. Receptor-negative (ERα−/
PR−) proliferating cells were rare in E-treated glands (4%).
In contrast, in E+P-treated glands, there were significantly
more proliferating receptor-negative cells.
E and P Regulate Expression of the Paracrine Growth
Factor, Amphiregulin
As shown above, most proliferation occurred in cells
expressing only PRB (Fig. 2g). Although PRB expression
Fig. 1 Hormonal regulation of cell-type-specific proliferation in the
normal mammary gland. a Immunofluorescent labeling with anti-
BrdU and anti-SMA antibody to identify luminal (BrdU positive/SMA
negative) and myoepithelial (BrdU positive/SMA positive) proliferat-
ing cells in ducts and lobules of OVX animals treated with vehicle
(C), E alone (E), P alone (P), or E+P was performed as described in
the “Methods” section. Bars represent mean ± SEM from three to five
animals per experimental group and 1,000 cells counted per animal.
*P<0.05 compared to control. b Immunoblot analysis of cell cycle
regulatory protein PCNA
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was maintained after OVX (Fig. 2a, b), E and P were both
required to induce robust proliferation. This suggested that
an E-induced paracrine factor(s) was required in addition to
P for proliferation in cells expressing only PRB.
Amphiregulin (Areg), a selective ligand of EGFR, has
previously been identified as an E-induced paracrine
factor that promotes proliferation of mammary epithelial
cells in the mouse [25]. Thus, we considered Areg, as a
Fig. 2 Hormonal regulation of PR isoform expression and colocalization
with ERα or proliferation. a–c Immunofluorescent labeling with PRA- and
PRB-specific antibody. The percentage of PR-positive cells in ducts (a) or
lobules (b) from ovary-intact (OI) or OVX animals treated with vehicle
(c), E, P, or E+P. Bars represent the mean ± SEM from three to five
animals per experimental group and 1,000 cells counted per animal. *P<
0.05. The percent of PRA+PRB+ cells is reduced compared to OI, E- or
E+P-treated groups. c Representative merged images of PRA (teal) and
PRB (magenta) expression in lobules from OI, C, E, P, or E+P-treated
glands. Yellow arrows indicate cells co-expressing PRA and PRB. White
arrows indicate cells expressing only PRB. d Immunoblot analysis of
PRB expression in whole mammary gland extracts. Uterine extract (UT)
was run as a positive control and was developed with antibody detecting
only PRB by immunoblot (hPRa6). e, f Colocalization of ERα with PR
isoforms. Representative merged images of immunofluorescent labeling
with anti-ERα (green) and e anti-PRA− (magenta) or (f) anti-PRB−
(magenta) antibodies in E+P-treated ducts. Yellow arrows indicate cells e
co-expressing ERα and PRA or f co-expressing ERα and PRB. White
arrows indicate cells expressing only PRB. Nuclei were counterstained
with DAPI. Scale bars, 50 μm. g Triple immunolabeling with PRA-,
PRB-, and BrdU-specific antibodies and quantitation of PR+BrdU+ cells.
Bars represent the mean ± SEM from five animals per experimental group
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potential E-induced paracrine mediator in the rat. Areg
was the most highly induced EGFR ligand by E or E+P
treatments (Fig. 3a). Treatment with E alone or E+P
increased Areg mRNA ∼18-fold, compared to a 5-fold
increase by P alone. Areg protein in whole gland extracts
was below the level of detection by immunoblot but could
be detected following immunoprecipitation. The level of
active Areg protein (43 kDa form) [26] was significantly
increased only in E+P-treated glands (Fig. 3b). The
50-kDa band that represents unprocessed Areg could not
be detected because it is masked by prominent IgG bands.
Areg protein was localized in cells co-expressing PRA and
PRB (these cells also co-express ER (Fig. 2e)), but not in
cells that express only PRB (Fig. 3c). In E-treated glands,
there were fewer cells expressing Areg than in E+P-treated
glands, and Areg expression was negligible in control or
P-treated glands.
RANKL and Wnt4 have also been identified as paracrine
mediators of P-induced proliferation in the mouse mamma-
ry gland [19, 27–29]. Therefore, we measured RANKL and
Wnt4 mRNA levels and compared them with Areg mRNA
expression (Supplemental Fig. 1). Both RANKL and Wnt4
were increased only in E+P and their levels were lower than
Areg. Since we observed an induction of both paracrine
factors by E+P treatment, we analyzed the expression
pattern of their respective downstream signaling molecules,
NFκB p65 and β-catenin [30, 31], by immunofluorescence.
However, we found no noticeable changes in intracellular
distribution or intensity of the staining for both NFκB p65
and β-catenin in E+P-treated glands compared to OVX
control glands (data not shown). Based on these results,
further experiments were focused on the role of Areg in
mediating E+P-induced proliferation.
Areg and P Are Sufficient to Induce Proliferation
After Ovariectomy In Vivo
To further investigate the potential role of Areg in
proliferation, the Elvax pellet mammary implant technique
was employed. Rats were OVX and implanted with a pellet
releasing a recombinant 11-kDa active fragment of Areg
protein; a control pellet was implanted in the contralateral
Fig. 3 Hormonal regulation of Areg expression and colocalization
with PR isoforms. a Real-time RT-PCR analysis of EGFR ligand
mRNA expression. Bars represent the mean ± SEM fold increase
compared to the level of EGF mRNA in OVX control. *P<0.05, that
hormone treated was greater than control. b Immunoblot analysis of
immunoprecipitated Areg protein. c Immunofluorescent colocalization
of Areg with PR isoforms. Representative confocal merged images of
Areg (green), PRB (red), and PRA (blue) staining in ducts. Yellow
arrows indicate cells expressing only PRB (red nuclei). White arrows
indicate cells that co-express Areg, PRB, and PRA. Green arrow
indicates cells co-expressing PRB and PRA but no Areg. Scale bar,
50 μm
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gland of the same animal. These animals were then treated
with vehicle control (C), E or P daily for 3 days.
Proliferation was analyzed by BrdU incorporation in
epithelial cells adjacent to pellet implants (Fig. 4). In E-
treated animals, a significant increase in proliferation was
observed only in Areg-implanted glands. In P-treated
animals, significantly more proliferation was observed in
Areg-implanted glands compared to Areg-implanted glands
of E-treated animals. Notably, only the Areg implant plus P
treatment induced proliferation comparable to that observed
with E+P treatment. Furthermore, the majority (98±2%) of
proliferating cells in both ducts and lobules in Areg-
implanted and P-treated glands expressed PRB.
E and P Increase EGFR Expression and Signaling
in the Normal Mammary Gland In Vivo
Since hormones regulated the expression of EGFR ligands,
we tested whether hormones influenced EGFR expression
and EGFR signaling. Indeed, EGFR mRNA (1.2-fold) and
protein levels (2-fold) were increased by E and E+P
treatment (Fig. 5a). Activation of EGFR by ligand binding
leads to activation of several intracellular signaling path-
ways, such as Akt, JNK, and Erk [9, 32, 33]. Immunoblot
analysis showed that E+P treatment produced the greatest
increase in phospho-Akt levels (Fig. 5b). C-Jun, a nuclear
transcription factor and member of activator protein-1 (AP-
1) complex is activated by JNK phosphorylation. Only E+P
increased phospho-c-Jun (Fig. 5b). Consistent with immu-
noblot results, immunofluorescence analyses showed that
phospho-Akt and nuclear phospho-c-Jun staining was
increased in epithelial cells by E+P treatment (Fig. 5c, d).
Activation of Erk signaling leads to induction of c-Fos,
another member of the AP-1 complex. Phospho-Erk levels
were increased similarly in E-, P- and E+P-treated glands
(Fig. 5b). However, c-Fos levels were increased only in E-
and E+P-treated glands (Fig. 5b). There was no significant
difference in the levels of phospho-EGFR among the
various treatment groups by immunoblot or immunohisto-
chemistry (data not shown), possibly due to an earlier and
transient EGFR phosphorylation.
Studies in T47D breast cancer cells have shown that
EGF treatment induces Erk-dependent PRB phosphoryla-
tion on serine residues [34]. Phosphorylated PRB is the
transcriptionally more active form of the receptor [13].
Consistent with findings in T47D human breast cancer cell
line, an analysis of PRB phosphorylation in hormone-
treated glands showed 1.9- and 2.4-fold increases in
phospho-PRB after E and E+P treatments, respectively
(Fig. 5e).
Fig. 4 Effect of Areg implants
plus hormone treatments on
proliferation. OVX animals
were implanted with Elvax
pellets containing Areg and
BSA control in the contralateral
gland and treated with vehicle
control (C), E alone, or P alone.
a Immunoperoxidase staining
with BrdU-specific antibody.
Representative images of ducts
adjacent to Areg or control
implants. Red arrows indicate
BrdU+ proliferating epithelial
cells. Yellow arrows indicate
BrdU+ proliferating stromal
cells. Asterisks indicate location
of Elvax implant. Scale bar,
100 μm. b, c Quantitation of
proliferating cells in ducts (b)
and lobules (c) adjacent to
control or Areg implants. Bars
represent the mean ± SEM
obtained from 3 to 5 animals per
treatment group and a minimum
of 500 epithelial cells counted.
*P<0.05
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P and Areg Cooperate to Induce Proliferation in Primary
Rat Mammary Organoids In Vitro
The effects of Areg, P, or Areg+P on proliferation were
also investigated in rat primary mammary organoids
cultured in collagen gels in serum-free media. In this
culture method, steroid receptor expression is main-
tained and the three-dimensional architecture and
organization of cells is similar to that observed in vivo
[19]. Both PRA and PRB were expressed in mammary
organoids and PRB was the predominant PR isoform
(Fig. 6a), as was observed in the normal mammary gland.
A significant increase in proliferation in both luminal and
myoepithelial cells was observed only with combined
Areg+P treatment which was decreased by either Iressa or
RU486, EGFR, and PR inhibitors, respectively (Fig. 6b).
Analysis of PRB expression and colocalization with
proliferation showed that 65.8±6.5% of BrdU-positive
epithelial cells expressed PRB in Areg+P-treated organo-
ids. These results indicate that both EGFR and PR
signaling were required for proliferation of mammary
organoids.
Fig. 5 Hormonal regulation of EGFR signaling. Mammary glands
were obtained from OVX animals treated with vehicle (C), with E
alone, P alone, or E+P. a Real-time PCR analysis of EGFR mRNA
and immunoblot analysis of EGFR protein expression. Bars represent
the mean ± SEM fold increase. *P<0.05 compared to OVX control. b
Immunoblot analysis of phospho-Akt, phospho-c-Jun, phospho-Erk,
and c-Fos expression in whole mammary gland extracts. c, d
Representative merged images of immunofluorescence analysis of c
phospho-Akt and d phospho-c-Jun in E- or E+P-treated glands. White
arrows indicate nuclear localization of phospho-Akt or phospho-c-
Jun. Yellow arrows indicate cytoplasmic phospho-Akt. Nuclei counter-
stained with DAPI (blue). Scale bar, 50 μm. e Immunoblot analysis of
phosphorylated PRB. Total protein was immunoprecipitated with a
mixture of anti-PR antibodies (DAKO and hPRa7). Phospho-PRB was
detected by immunoblot with phospho-serine-specific antibody (pri-
mary mouse mAb and IRDye™800-labeled secondary antibody),
followed by incubation with PRB-specific antibody (primary rabbit
polyclonalB15, 1:500; IRDye™680-labeled secondary antibody).
Simultaneous detection and colocalization of the two antibodies
(anti-phospho-serine and anti-PRB) was used to measure the level of
phospho-PRB. Total PRB and phospho-PRB are shown separately.
Numbers above bands indicate fold change compared to OVX control
after normalization to b β-actin or e IgG
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Progestin and Areg Cooperatively Induce Proliferation
in T47D Breast Cancer Cells Expressing PRB
The cross talk between P and EGF signaling in the T47D
breast cancer cell line is well documented, and PRB has
been shown to mediate the interaction between PR and
EGFR signaling [9–11]. We asked whether Areg interacted
with P signaling in a manner similar to EGF in T47D cells.
To determine the relative contribution of PR isoforms,
T47D cells lacking PR (Y), expressing only PRA (YA), or
only PRB (YB) were used. Phosphorylation of Akt and Erk
was analyzed by in-cell Western as a measure of EGFR
activation (Fig. 7a–d). Akt phosphorylation was slightly
increased by Areg or Areg+R5020 only in YB cells
(Fig. 7a). Either Iressa or RU486 significantly decreased
Areg+R5020-induced phospho-Akt (Fig. 7b). Phospho-Erk
was slightly increased in YA cells by R5020 or Areg+
R5020 and dramatically increased with Areg+R5020 in YB
cells, which was inhibited by either Iressa or RU486
(Fig. 7c, d). These results indicated that YB cells were the
major responders to Areg and R5020 and that Areg and
R5020 through binding EGFR or PRB, respectively,
cooperated to induce Erk phosphorylation. Consistent with
the induction of proliferation only by Areg+P treatment in
mammary organoids, only Areg+R5020 significantly in-
creased in the percentage of YB cells in S phase that was
efficiently reduced to basal levels by either Iressa or RU486
(Fig. 7e).
E + P Treatment Increases Proliferation
in Hormone-Dependent Rat Mammary Cancers
Mammary tumors (adenocarcinomas) were obtained from
carcinogen-treated, OVX rats treated continuously with E
alone or E+P. As previously reported, these tumors are
hormone-dependent and express ERα and PR [35] similar
to hormone-dependent human breast cancers, the predom-
inant type of human breast cancer. Individual tumors in the
E and E+P-treated groups varied with respect to prolifer-
ation as measured by BrdU incorporation. However, on
average, E+P treatment produced significantly greater
proliferation than E alone (Fig. 8a). Consistent with this,
the average level of PCNA protein was greater in E+P-
treated tumors compared to E-treated tumors (2.2±0.3-fold
increase, P<0.05; n=5 tumors/group) (Fig. 8b). Notably,
there was a change in PR isoform expression. Tumors
arising in E-treated rats contained significantly more cells
expressing only PRA and significantly fewer cells express-
ing only PRB compared to tumors arising in E+P-treated
rats (Fig. 8c). Overall, cells within tumors arising in both E
and E+P-treated rats had greater percentages of cells
expressing only PRA and decreased percentages of cells
expressing only PRB (Fig. 8c) compared to normal glands
of ovary-intact and hormone-treated rats (Fig. 2a, b).
E + P Treatment Leads to a Greater Activation of EGFR
Pathway in Mammary Cancers Compared to E Treatment
There was no significant difference in EGFR or Areg
mRNA expression in E vs. E+P-treated tumors (Fig. 9a, b).
Areg was highly expressed in both E and E+P-treated
tumors. In contrast to the normal gland, Ereg was also
increased in E and E+P-treated tumors (Fig. 9b). Areg
protein was expressed in numerous cells in both E and
E+P-treated tumors in PRA+PRB+ and in PRA+PRB−
cells (Fig. 9c). Areg could be detected in tumor extracts
without requiring immunoprecipitation. While individual
tumors varied with respect to Areg levels (50 and 43 kDa
forms), on average there was no significant difference
between E and E+P-treated tumors (n=5–7 tumors/group)
(Fig. 9d). However, E+P treatment led to the increased
phosphorylation of Akt and JNK (1.8±0.3 and 1.4±
Fig. 6 P and Areg signaling are required for proliferation in primary
mammary organoids in vitro. a Merged images of representative PRA
and PRB in organoids. Nuclei were counterstained with DAPI (blue).
White arrows indicate cells expressing PR. Scale bar, 25 μm. b Effect
of EGFR inhibitor, Iressa, and PR inhibitor, RU486, on proliferation
of organoids. Quantitation of proliferating myoepithelial (BrdU
positive/SMA positive) and luminal (BrdU positive/SMA negative)
cells. Bars represent mean ± SEM; 1,000 epithelial cells counted per
treatment. *P<0.05, that Areg+P was greater than all treatment
groups. #P<0.05, that Areg+P combined with either Iressa or
RU486 treatment was significantly less than Areg+P
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0.1-fold increases, respectively) (P<0.05; n=3–5 tumors/
groups), whereas phospho-Erk levels were not significantly
different in E- and E+P-treated tumors (Fig. 9d).
We also analyzed expression of RANKL and Wnt4 in
hormone-treated mammary tumors (Supplemental Fig. 2).
Notably, Areg expression was by far greater than RANKL
or Wnt4 mRNA expression in both E- and E+P-treated
tumors.
Discussion
In the present study, we investigated the molecular and cellular
mechanisms underlying E and/or P-induced proliferation, in the
rat normal mammary gland and in hormone-dependent rat
mammary cancers. The rat was chosen for these studies
because ERα, PRA, and PRB exhibit cell-type-specific
localization remarkably similar to the adult premenopausal
Fig. 7 PR and EGFR signaling and proliferation in T47D breast
cancer cells. T47D breast cancer cell lines expressing only PRA (YA),
only PRB (YB), or lacking PR (Y) were treated with basal media
(BM), R5020, Areg, or Areg+R5020, and analyzed with a phospho-
Akt or c phospho-Erk antibody as described in the “Methods” section.
The effect of Iressa or RU486 on b Akt or d Erk phosphorylation in
T47D-YB cells. Bars represent the mean ± SEM from a representative
experiment. a–d *P<0.05 for comparisons indicated. e Cell cycle
analysis in treated T47D-YB cells. *P<0.05, that the percentage of
cells in S phase in Areg+R5020 was greater compared to other
treatments. #P<0.05, that Areg+R5020 combined with either Iressa or
RU486 treatment was significantly less than Areg+R5020
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human breast. [14, 36]. Importantly, these studies were carried
out in vivo and therefore may provide information relevant to
in vivo P action in the human breast and breast cancer.
Hormonal Regulation of PR Isoform Expression
and Proliferation in the Normal Gland
The rat mammary gland contains three populations of luminal
epithelial cells: cells that co-express ERα, PRA, and PRB;
cells that express only PRB; and cells that are ERα, PRA, and
PRB negative. Cells expressing only PRB are also observed in
the normal human premenopausal breast [14] and in the
pregnant mouse mammary gland [37]. As reported by others
[38], we found that PRA expression was E dependent. In
contrast, PRB expression was E and P independent being
equally expressed in OVX and hormone-treated glands. This
is consistent with the previous observation that only PRB is
expressed prior to significant production of ovarian hor-
mones in the pre-pubertal rat mammary gland [21]. In the
human breast, an overall reduction of PR expression has
been shown after menopause [39] compared to the premen-
opausal breast [36], presumably due to reduced estrogen
levels. However, it is not known whether PRA and PRB are
differentially regulated after menopause.
In OVX rats, E+P treatment produced significantly
greater proliferation than treatment with E alone. The
majority of proliferation occurred in cells expressing only
PRB or in cells that were ERα, PRA, and PRB negative.
Multiple studies in the human breast and rodent mammary
glands have reported that proliferation occurs mostly in
ERα/PR-negative cells [37, 40, 41]. While our results may
seem at odds with these previous reports, it is important to
point out that many commercially available anti-PR anti-
bodies detect only PRA and not PRB by immunohisto-
chemistry [20]. Thus, it is quite possible that previous
reports failed to detect PRB in proliferating cells. Since a
sub-population of cells that express only PRB are also
ERα/PRA negative in the rat and human [14, 21], the
proliferating PRB expressing cells in those studies would
have been considered to be ERα, PR negative.
Areg, an Autocrine/Paracrine Mediator of P-Induced
Proliferation
The requirement of both E and P for induction of robust
proliferation despite abundant PRB expression after OVX
led us to consider that an E-induced paracrine factor in
addition to P was required for proliferation. Based on
studies of E-induced Areg, an EGFR ligand in mouse
mammary gland [25] and P action in T47D breast cancer
cells, as well as the interaction of PR and EGFR, we
investigated EGFR ligands as potential candidates of the E-
induced paracrine factor. Within the 3-day time frame of
hormone treatments herein, Areg was by far the most
highly E-induced EGFR ligand in the rat mammary gland.
The human Areg gene has a putative estrogen response
element [42] and Areg expression is strongly induced by E
in the human breast [43]. Thus, E-induced Areg expression
in the rat is consistent with findings in the human and
mouse mammary glands. In the rat, despite the increased
Areg mRNA levels induced by E, the highest level of Areg
protein was observed only in E+P-treated glands and was
detected in cells expressing ERα, PRA and PRB, but not in
cells expressing only PRB. Differential regulation of Areg
mRNA and protein has been previously observed in human
Fig. 8 Hormonal regulation of proliferation and PR isoform expres-
sion in hormone-dependent rat mammary tumors. Mammary tumors
were obtained from carcinogen-treated OVX animals implanted with
E alone or E+P. a Tumor cell proliferation was assessed by BrdU
incorporation. Individual tumors (n=16–22 per treatment group) are
represented by a single dot. Mean ± SEM obtained from 1,000 cells
counted per tumor. *P<0.05. b Immunoblot analysis of PCNA in
tumor extracts. Numbers above bands indicate normalized intensity of
PCNA band. c The percentage of PR-positive cells in E or E+P-treated
tumors. Bars represent the mean ± SEM from five tumors per
experimental group with 1,000 tumor cells counted. *P<0.05 that
percent of cells expressing only PRA is increased and cells expressing
PRB only is decreased in E-treated tumors
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eosinophils [44]. Our findings indicate that P acting
through PRA and/or PRB may stabilize or stimulate
translation of Areg protein in the rat mammary gland.
That Areg, an E-induced paracrine factor, could replace
E and act in concert with P to induce robust proliferation in
vivo was demonstrated in the Elvax pellet implant experi-
ments. The majority of proliferating cells expressed PRB.
Likewise, in mammary organoids in vitro, the combination
of Areg+P also dramatically increased proliferation. Nota-
bly, both PR and EGFR signaling were necessary for the
proliferative response. Analysis of proliferation (percent of
cells in S phase) in T47D cells expressing only PRB, also
demonstrated that only Areg+R5020 increased proliferation
compared to Areg or R5020 alone and could be inhibited
by either Iressa or RU486. These results suggest that Areg
acting through EGFR and P acting through PRB cooperate
to induce proliferation.
P-dependent paracrine factors, RANKL and Wnt4, were
also induced by E+P treatment in OVX glands. However,
intra-cellular localization of their respective downstream
targets, NFκB p65 and β-catenin, was not altered by E+P
treatment. Thus, compared to Areg, it appears that under
the current experimental conditions (OVX followed by
3 days of hormone treatment), RANKL and Wnt4 have a
lesser effect on proliferation.
Interactions Between P, E, and EGFR Signaling
The E-dependent upregulation of EGFR protein expression
that was observed in the normal gland likely enhances
responsiveness to Areg. Areg binding to EGFR can activate
Akt, JNK, and Erk [9, 33, 45]. We found that E+P
treatment of the normal gland markedly activated not only
Akt, a key regulator of cell proliferation and survival [46],
but also c-Jun, a molecular target of JNK. Importantly, both
phospho-Akt and phospho-c-Jun were detected in luminal
epithelial cells, consistent with EGFR signaling occurring
in the mammary epithelium.
Activation of JNK and Erk leads to formation of an
activated AP-1 transcription complex (phospho-c-Jun/c-Fos
Fig. 9 Hormonal regulation of EGFR signaling in E- or E+P-treated
tumors. a, b Real-time RT-PCR analysis of a EGFR and b EGFR
ligand mRNA levels. Bars represent the mean ± SEM fold change
compared to levels in E-treated tumors (n=4–5 tumors/group). c
Representative merged images of immunolabeling with Areg- (green),
PRA- (blue), and PRB- (red) specific antibodies. White arrows
indicate cells co-expressing Areg and PRA. Yellow arrows indicate
cells co-expressing Areg, PRB, and PRA. Scale bar, 75 μm. d
Immunoblot analysis of Areg, phospho-Akt, phospho-JNK, and
phospho-Erk for the same E- or E+P-treated tumors. Numbers above
bands indicate relative band intensity normalized to β-actin
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heterodimer) important for cell proliferation [47]. While c-
Fos was equally increased by E or E+P treatment, phospho-
c-Jun was increased only by E+P, suggesting that both E
and P were required for activation of AP-1. In the mouse,
the blockade of AP-1 function results in decreased
proliferation, stunted mammary gland growth, and reduced
sidebranching, suggesting a pivotal role for AP-1 in
epithelial proliferation [48]. E+P treatment also increased
PCNA protein, a promoter of cell cycle progression.
Interestingly, PCNA has been identified as a PRB-
dependent gene in T47D breast cancer cells [49]. We
speculate that in the rat mammary gland PCNA transcrip-
tion is also driven by liganded PRB.
Extensive cross talk between EGF and P signaling has been
shown in T47D breast cancer cells [9, 10, 50]. EGF induces a
transient phosphorylation of Ser294 in PRB in an Erk-
dependent manner [10]. This phosphorylation causes nuclear
translocation of un-liganded PRB and renders PRB more
sensitive to ligand [10]. In this study, we found that PRB
phosphorylation of serine residues was increased in vivo by E
and further increased after E+P treatment in the normal gland.
Thus, the observed phosphorylation of PRB is consistent with
Areg production and activation of EGFR signaling in the
epithelium and correlates with proliferation of cells express-
ing PRB. This suggests that phosphorylation of PRB may
enhance the transcriptional activity of PRB in vivo.
Interaction Between P and Areg Is Mediated by PRB
Consistent with published data describing PR and EGFR
cross talk [9], we demonstrated in T47D breast cancer cells
that P signaling via PRB, but not PRA, cooperated with
Areg signaling. Areg and R5020 acting via PRB synergis-
tically induced Erk phosphorylation and increased prolifer-
ation. Inhibitors of EGFR or PR efficiently blocked Erk
phosphorylation, providing evidence that both pathways
were required for robust Erk phosphorylation. Interestingly,
Areg treatment induced only modest Akt phosphorylation
in PRB expressing T47D cells that was only slightly
increased by the addition of R5020. These data indicate
that Erk is the major downstream target of the interaction
between EGFR and P signaling in T47D-YB cells. A
diagram summarizing the interactions between ERα, PRA,
PRB, and EGFR signaling in the normal rat mammary
gland is presented in Fig. 10.
Comparison of E, P, and the EGFR Signaling in the Normal
Mammary Gland and Mammary Cancers in the Rat
The combination of E+P was more potent than E alone in
promoting proliferation in both normal mammary glands
and in mammary tumors that developed in hormone-treated
rats. The proliferation rates elicited by E or E+P in tumors
were not significantly different from those in normal
glands. These results suggest that endogenous P in
premenopausal women and exogenous P in combined
estrogen+progestin hormonal therapy in postmenopausal
women may also contribute to tumor proliferation.
The percent of cells co-expressing PRA and PRB was
not significantly different between E and E+P-treated
normal mammary glands. However, tumor development
was notably associated with an increased percentage of
cells expressing only PRA and a reduced percentage of
cells expressing only PRB. Thus, altered PR isoform
expression in tumors may lead to the increased P signaling
via PRA. Predominance of PRA expression has been
detected in early precancerous lesions of the human breast
suggesting that increased PRA expression is an event
associated with the early stages of cancer development
[36]. In breast cancers, the predominance of PRA expres-
sion is associated with a more aggressive tumor phenotype
and worse prognosis for overall survival [51]. Studies in
human breast cancer cells have also demonstrated that PRA
activates transcription of several genes that are associated
with cell transformation and cell motility and may confer a
more aggressive cellular phenotype [52]. However, there is
another possible mechanism to be considered to explain the
observed reduced percentage of PRB positive cells and
increased percentage of PRA positive cells in tumors from
E+P-treated rats. This change could be the result of
increased PRB phosphorylation and rapid receptor turnover
leading to a lack of detection by immunohistochemistry.
Rapid turnover of PRB is reported to be related to increased
Fig. 10 Diagram of convergence of E, P, and EGFR signaling pathways.
1 E acting via ERα and P acting via PRA/PRB induce Areg mRNA
expression and protein in ERα+PRA+PRB+ cells. 2 Secreted Areg acts
in a paracrine manner and activates EGFR signaling in ERα−PRA−
PRB+ cells and 3 in an autocrine manner in ERα+PRA+PRB+ cells
and activates EGFR signaling. EGFR signaling activates Akt (4), JNK
(5), and Erk (6) leading to formation of AP-1 complex (phospho-c-Jun/
c-Fos). 4 PRB may enhance Akt phosphorylation. 7 Activation of Erk
leads to phosphorylation of PRB. 8 Activated AP-1 and liganded
phospho-PRB induce cell cycle regulatory protein PCNA and prolifer-
ation in ERα+PRA+PRB+ and ERα−PRA−PRB+ cells
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transcriptional activity in T47D human breast cancer cells
expressing the PRB isoform in the presence of ligand [53].
This could also explain the increased proliferation observed
in tumors arising in E+P-treated rats.
Based on mRNA levels, relative EGFR levels were
similar in E- and E+P-treated normal glands and tumors.
Analysis of mRNA expression showed that Areg was the
most highly expressed EGFR ligand in normal glands and
highly expressed in tumors. It should be noted that Ereg
levels were similar to Areg levels in tumors and therefore
may contribute to proliferation in tumors. In the normal
gland, Areg protein was highly induced only in the
presence of E+P. However, in tumors, treatment with either
E alone or E+P induced comparable levels of Areg protein.
Interestingly, increased Areg protein was not detected in
normal mammary cells adjacent to tumors (data not shown).
This suggests that increased Areg expression was specifi-
cally associated with tumor development and not merely
the result of the chronic hormone exposure.
Our results obtained in vivo in the normal rat gland, in
rat primary mammary organoid cultures, and in T47D YB
cells demonstrated that Areg signaling via EGFR cooper-
ates with P signaling to promote proliferation. Consistent
with this, we also observed a marked activation of signaling
pathways downstream of EGFR in E+P-treated normal
mammary glands and in E+P-treated tumors compared to
treatment with E alone. However, it should be noted that
there was significant variability among tumors in the two
treatment groups. These results indicate that the interaction
between P and EGFR signaling that drives proliferation in
the normal mammary gland is similarly functional in a
subset of tumors. The results in the rat mammary gland and
mammary cancer suggest that Akt phosphorylation can
serve as an indicator of ongoing P and EGFR cross talk. In
T47D YB cells, Areg+R5020 increased phosphorylation of
Erk to a greater extent than Akt. The difference between
signaling inT47D cells and signaling in the normal rat
mammary gland and tumors may be due to intrinsic species
differences in EGFR signaling. It is also possible that
dependence on Erk activation may be specific to T47D
cells and does not necessarily reflect the features of all
human primary hormone-dependent breast cancers. Despite
this difference between rat mammary cancers and T47D
breast cancer cells, the cross talk between E, P, and EGFR
signaling (i.e., Areg production, Akt phosphorylation, Erk
phosphorylation) may present important molecular markers
and targets for the treatment of hormone-dependent
mammary cancers that develop in premenopausal women.
In this regard, inhibition of EGFR phosphorylation by
Iressa blocked Areg+P-induced proliferation in primary
mammary organoids and markedly inhibited Areg+P-
induced Erk phosphorylation that was associated with
proliferation in T47D-YB cells. Iressa has been shown to
reduce mammary tumor incidence and cause tumor regres-
sion in carcinogen-treated rats [54]. Furthermore, the
combination of Iressa and an aromatase inhibitor was more
effective than Iressa alone [54]. Iressa is currently under
investigation in clinical trials for the treatment of breast
cancer patients. In a recent trial, Iressa treatment showed a
better clinical benefit rate in chemotherapy-naive patients
with hormone-dependent breast cancers than in patients
with hormone-independent cancers [55]. Our results that
demonstrate E, P, and EGFR cross talk in hormone-
dependent rat mammary cancers provide a plausible
explanation for this clinical finding.
Progestins continue to be highly implicated in the
etiology of human breast cancer [56]. Recently RANKL,
a P-induced paracrine factor, has been implicated in the
development of mammary cancer in the mouse [57, 58]. In
the rat (Kariagina and Haslam, unpublished observations)
and mouse normal mammary gland [59], RANKL is
produced only in cells that express PRA. It should be
noted that rat and the mouse mammary glands differ with
regard to developmental expression, hormonal regulation,
and colocalization of PRA and PRB. In the mouse, PRA
and PRB are generally expressed in different cells, PRA
expression is significantly maintained after OVX [8], and
RANKL can be induced by P alone [59]. In the rat,
virtually no PRA is detectable after OVX, and RANKL
induction requires combined E+P treatment (Supplemental
Fig. 1). In contrast to the mouse, the pattern of PRA and
PRB expression and colocalization of both isoforms in the
same cell in rat closely resembles the pattern observed in
the human breast [14, 21]. The majority of carcinogen-
induced mammary tumors in the rat are ER+PR+ and
hormone dependent in contrast to mouse mammary cancer
models which are predominantly ER−PR− and hormone
independent. Furthermore, E-treated rats develop mammary
cancer in the absence of RANKL expression (Supplemental
Fig. 2). This raises the possibility that Areg may be a more
relevant E+P-induced mediator of the development of
hormone-dependent human breast cancer. While a role of
RANKL has not yet been identified in the development of
hormone-dependent mammary cancer in the rat, its poten-
tial role in tumor cell proliferation and tumor behavior
warrants further investigation.
In conclusion, the present study demonstrates that E and
P interact with EGFR signaling through Areg to induce
proliferation in the normal mammary tissue and hormone-
dependent mammary cancer. Inhibition of EGFR may be a
promising therapeutic strategy to be used in combination
with anti-hormone therapies for the treatment of hormone-
dependent breast cancers that exhibit activation of EGFR
signaling. This may be particularly relevant for premeno-
pausal women who produce endogenous progesterone. The
results obtained herein also indicate that the rat is a relevant
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model for testing therapeutic strategies that can block this
signaling pathway.
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